A company, Phoenix Molecular Designs, is on a mission to help thousands of triple-negative breast cancer patients and their families. The company announced the appointment of Mike Varney, Ph.D., to its advisory board. Sandra Dunn, Ph. D., Founder, and CEO of the company, said, “Our vision is clear – to be the first to market RSK inhibitors for TNBC, and we believe that Mike’s leading expertise in drug design and discovery will help us as we work towards that goal.”
Mike Varney said, “I am very pleased to be part of Phoenix Molecular Designs and their distinguished advisory board.” He feels that Sandi and her team are industry leaders. He says that they have made tremendous progress in the development of a potential new therapy targeting TNBC. A recent development has also been seen in the team, which is companion diagnostics (CDx) measuring activated RSK2 in breast cancers. To date, the data obtained from the pre-clinical studies on ongoing clinical studies of PMD-026 shows excellent potential in delivering a higher quality of life for those battling TNBC.